MC 4232

Drug Profile

MC 4232

Alternative Names: MC-1/lisinopril; MC-4232; Pyridoxal phosphate/lisinopril

Latest Information Update: 18 Aug 2014

Price : $50

At a glance

  • Originator Medicure
  • Class Antihypertensives; Coenzymes; Dipeptides; Ischaemic heart disorder therapies; Picolines
  • Mechanism of Action ACE inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic complications; Hypertension

Most Recent Events

  • 18 Aug 2014 Discontinued - Phase-II for Hypertension in Canada (PO)
  • 18 Aug 2014 Discontinued - Phase-II for Diabetic complications in Canada (PO)
  • 26 Sep 2005 Medicure has completed a phase II MATCHED trial in patients with diabetes and hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top